Overview

The ProNeura platform is ideal for treating select chronic diseases for which low dose, long-term delivery of non-fluctuating medication levels may offer advantages over oral administration. In addition to our current late-stage program for opioid addiction and pre-clinical programs for Parkinson's disease and hypothyroidism, Titan is reviewing compounds and conducting feasibility studies on candidates that potentially fit the ProNeura profile, such as those for the treatment of certain hormonal deficiencies, type 2 diabetes, attention deficit hyperactivity disorder, benign prostate hyperplasia and others.

Candidate Indication Development Stage
Probuphine® Opioid Addiction
Market completed
Market completed
Market completed
Market completed
Market in progress
Preclinical Phase 1 Phase 2 Phase 3 Market
Ropinirole Implant Parkinson's Disease
Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market
T3 Implant Hypothyroidism
Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market

The ProNeura Long-term, Continuous Drug Delivery Platform

ProNeura is designed to provide continuous drug release with non-fluctuating medication levels over a period of three months to a year. It is ideal for treating chronic diseases for which the maintenance of stable medication levels could offer advantages over other routes of administration.

Learn More About ProNeura Watch MOA Video